Delivery Order SPE2DE24D0013-SPE2D625F2WDD
- Not listed
- The U.S. Defense Department's Medical Supply Chain organization awarded a $2,835 firm fixed-price delivery order to Cepheid Inc. on August 29, 2025, for molecular diagnostic testing solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) detection. The delivery order, which extends through September 8, 2025, will be performed at Cepheid's facility in Sunnyvale, California. This award carries no small business set-aside designation and represents a continuation of...
- The Defense Department's Medical Supply Chain division awarded a $3,400 firm fixed-price delivery order to Cepheid Inc. on July 30, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The contract, designated as delivery order XPCOV2/FLU/RSV-10, is scheduled for completion by August 6, 2025, and will be performed at Cepheid's facility in Sunnyvale, California. This award carries no set-aside designation and represents a...
- The Defense Department's Medical Supply Chain awarded a $4,080 firm fixed-price delivery order to Cepheid Inc. on July 18, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The contract, designated as XPCOV2/FLU/RSV-10, represents a delivery order with an ultimate completion date of July 25, 2025, and carries no set-aside designation. Work will be performed at Cepheid's facility in Sunnyvale, California. This award reflects...
- The U.S. Department of Defense's Medical Supply Chain awarded a $13.6K firm fixed-price delivery order to Cepheid Inc. on September 4, 2025, with completion scheduled for September 11, 2025. This delivery order, designated XPCOV2/FLU/RSV-10, procures molecular diagnostic testing solutions from the Sunnyvale, California-based manufacturer, likely supporting COVID-19, influenza, and respiratory syncytial virus (RSV) detection capabilities across military healthcare systems. The award carries no...
- The Defense Department's Medical Supply Chain awarded a $17,280 firm fixed-price delivery order to Cepheid Inc., a molecular diagnostics manufacturer based in Sunnyvale, California, on September 3, 2025, with completion targeted for September 10, 2025. This delivery order, designated XPCOV2/FLU/RSV-10, carries no set-aside designation and procures diagnostic testing solutions, likely reagents and assays for COVID-19, influenza, and respiratory syncytial virus detection based on the contract...
- The U.S. Defense Logistics Agency's Medical Supply Chain division awarded a $17,000 firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28) on August 19, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus testing. The contract, designated as XPCOV2/FLU/RSV-10, has an ultimate completion date of August 26, 2025, and will be performed at Cepheid's headquarters in Sunnyvale, California. No small business set-aside was utilized for...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $13,096.80 to Cepheid Inc. on July 28, 2025, for molecular diagnostic testing solutions. This firm fixed-price delivery order, designated 4568920464 and titled XPCOV2/FLU/RSV-10, carries an ultimate completion date of August 11, 2025, and will be performed at Cepheid's facility in Sunnyvale, California. The contract involves diagnostic testing capabilities for COVID-19, influenza, and respiratory syncytial...
- The U.S. Defense Department's Medical Supply Chain awarded a $8,160 firm fixed-price delivery order to Cepheid Inc., a molecular diagnostic solutions manufacturer based in Sunnyvale, California, on September 2, 2025. This delivery order, designated 4569302270 for XPCOV2/FLU/RSV-10 testing solutions, is scheduled for completion by September 9, 2025, with work performed at the contractor's Sunnyvale facility. The award carries no small business set-aside designation and represents part of...
- The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $5,440 to Cepheid Inc. on August 25, 2025, for the supply of COVID-19, influenza, and respiratory syncytial virus (RSV) diagnostic solutions. This firm fixed-price delivery order, which is not set-aside designated, is scheduled for completion by September 2, 2025, and will be performed at Cepheid's facility in Sunnyvale, California. The award represents a continuation of Cepheid's established role...
- The U.S. Defense Department's Medical Supply Chain awarded Cepheid Inc., a Sunnyvale, California-based molecular diagnostics manufacturer, a firm fixed-price delivery order valued at $20,400 on August 11, 2025, with an ultimate completion date of August 18, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, involves diagnostic testing solutions for COVID-19, influenza, and respiratory syncytial virus (RSV)—infectious diseases commonly detected through Cepheid's GeneXpert molecular...
- SPE2DE24D0013Indefinite Delivery Contract
- SPE2DE24D0013-SPE2D625F2WDDDelivery Order
The U.S. Defense Department's Medical Supply Chain awarded a $17,680 firm fixed-price delivery order to Cepheid Inc. on September 8, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The delivery order, designated XPCOV2/FLU/RSV-10, is set to be completed by September 15, 2025, with performance conducted at Cepheid's headquarters in Sunnyvale, California. This award carries no set-aside designation and represents a continuation of Cepheid's established role as a key federal supplier of point-of-care diagnostic systems and reagents. This delivery order is likely issued under one of Cepheid's existing Defense Department or Veterans Affairs indefinite delivery contracts that authorize ongoing procurement of the company's GeneXpert diagnostic systems and associated test kits. Cepheid holds substantial IDV vehicles with the VA's Veterans Integrated Service Networks, including a $32.8 million single-award contract through September 30, 2030, that covers molecular diagnostic testing reagents and assays. The company specializes in rapid, accurate detection of infectious diseases across federal healthcare systems, making this delivery order part of a broader federal strategy to maintain diagnostic testing capacity for respiratory pathogens across defense and veteran health networks.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.7k | 9/8/25 |